Eylea has historically commanded a dominant Eylea Market Share within the global anti-VEGF category, frequently leading its nearest branded competitor, Lucentis (ranibizumab), and successfully competing against the extensive off-label use of Avastin (bevacizumab). This leadership position was largely secured by Eylea’s superior clinical profile, demonstrating greater durability and allowing for longer treatment intervals than its initial rivals, which translated directly into better patient and physician preference. The Eylea Market Share is a critical metric for the parent companies, Regeneron and Bayer, reflecting their commercial success and the drug’s perceived value in the ophthalmology community. However, this share is now under threat from multiple directions, necessitating a robust and multifaceted defense strategy.

The first major challenge to Eylea Market Share is the introduction of Novartis’s Vabysmo (faricimab), a bispecific antibody that targets both VEGF-A and Ang-2, offering a new mechanism of action and also demonstrating the capability for extended dosing intervals, thus competing directly with the high-dose Eylea HD. The second, and arguably more significant, threat is the impending loss of patent exclusivity and the subsequent launch of aflibercept biosimilars. The entry of these biosimilars will inevitably chip away at the market share of the legacy 2 mg product, primarily through aggressive pricing strategies targeting payers and healthcare systems. Regeneron's strategic response—the launch of Eylea HD—is a direct defense mechanism intended to establish a new, clinically superior, and patent-protected product line. By transitioning a majority of the patient base to Eylea HD, the company aims to protect its overall revenue and maintain a commanding Eylea Market Share in the premium segment of the anti-VEGF market. The battle for market share will be won not only on efficacy but on the combination of extended dosing convenience, superior real-world data, and strategic payer negotiations to ensure Eylea HD is favored for new patient starts and seamless switching for existing patients. For a comprehensive look at the market, see this Eylea Market Share.